On Oct. 22, Roche reported 7% growth at constant exchange rates (8% pharma, 5% diagnostics) in the third quarter, and management maintained full-year guidance for mid-single-digit sales and high-single-digit core EPS growth, also at constant rates. Shares traded flat.
Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.
Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.72 | 44.18 | 26.35 |
Price/Book Value | 9.72 | 8.35 | — |
Price/Sales | 5.10 | 5.29 | 7.89 |
Price/Cash Flow | 15.98 | 15.88 | 21.73 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 6.27% | 14.29% |
Return on Equity (Normalized) | 48.77% | 16.68% | — |
Return on Invested Capital (Normalized) | 23.90% | 9.82% | 32.02% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|?z&%<Y^ | LOCK|Hs | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|MxSY%> | LOCK|FX% | $647B | |||
| AbbVie Inc
ABBV
| LOCK|&n<G$G | LOCK|>vY | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|V@qc&>d | LOCK|zw | $385B | |||
| Merck & Co Inc
MRK
| LOCK|CYnDH@ | LOCK|zx | $350B | |||
| Novartis AG ADR
NVS
| LOCK|?Vz%>N$ | LOCK|h@ | $294B | |||
| AstraZeneca PLC
AZN
| LOCK|%?lWq@l! | LOCK|fr | $265B | |||
| Amgen Inc
AMGN
| LOCK|$Ly?DL# | LOCK|&!? | $242B | |||
| Gilead Sciences Inc
GILD
| LOCK|NGqQj>W | LOCK|@P$ | $197B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!>lhZn | LOCK|#Ys | $171B |
United States